These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 2355446

  • 21. Clinical inquiries. Should liver enzymes be checked in a patient taking niacin?
    Rizakallah GS, Mertens MK, Brown ML, Sanner L.
    J Fam Pract; 2005 Mar; 54(3):265-8. PubMed ID: 15755381
    [No Abstract] [Full Text] [Related]

  • 22. Pharmacoepidemiology of niacin.
    Jungnickel PW, Maloley PA.
    Ann Intern Med; 1995 Mar 01; 122(5):392-3. PubMed ID: 7847654
    [No Abstract] [Full Text] [Related]

  • 23. The prevalence of side effects with regular and sustained-release nicotinic acid.
    Gibbons LW, Gonzalez V, Gordon N, Grundy S.
    Am J Med; 1995 Oct 01; 99(4):378-85. PubMed ID: 7573093
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Adverse effects of sustained-release niacin.
    Knapp TR, Middleton RK.
    DICP; 1991 Mar 01; 25(3):253-4. PubMed ID: 2028632
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. A case for immediate-release niacin.
    Bassan M.
    Heart Lung; 2012 Mar 01; 41(1):95-8. PubMed ID: 21414665
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Pharmacology of niacin or nicotinic acid].
    Santos RD.
    Arq Bras Cardiol; 2005 Oct 01; 85 Suppl 5():17-9. PubMed ID: 16400392
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Safety and side effects of sustained-release niacin.
    Shields M, Beckmann SL.
    JAMA; 1994 Aug 17; 272(7):514; author reply 514-5. PubMed ID: 8046797
    [No Abstract] [Full Text] [Related]

  • 35. Safety of extended-release niacin/laropiprant in patients with dyslipidemia.
    McKenney J, Bays H, Koren M, Ballantyne CM, Paolini JF, Mitchel Y, Betteridge A, Kuznetsova O, Sapre A, Sisk CM, Maccubbin D.
    J Clin Lipidol; 2010 Aug 17; 4(2):105-112.e1. PubMed ID: 21122637
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Safety and side effects of sustained-release niacin.
    Keenan JM, Ripsin CM, Huang Z, McCaffrey DJ.
    JAMA; 1994 Aug 17; 272(7):513; author reply 514-5. PubMed ID: 8046795
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.